Orphan Technologies is committed to reduce the burden of patients suffering from elevated homocysteine levels. OT-58, our lead drug development candidate, has been optimized as an enzyme therapy for classical homocystinuria, a genetic disease characterized by debilitating cardiovascular, skeletal, neurologic, and ophthalmologic complications. OT-58 is designed to reduce homocysteine levels via a targeted mechanism of action and may have therapeutic applications in other diseases.
“... after my brother had issues with his eyesight the eye doctor referred or entire family to a geneticist to be tested for homocystinuria...”
“... OT-58 is designed to help patients reduce their homocysteine levels and restore a normal lifestyle.”
October is #Homocystinuria Awareness month. @HCUNetworkAmerica Show your support and share the #HCUAwareness Ribbon